Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
 

Corporate Investor Presentation

Rigel Corporate Investor Presentation
More »
Recent News
DateTitle 
08/08/18
Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update

$1.8 Million in Net Product Sales for TAVALISSE™ (fostamatinib disodium hexahydrate) Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 8, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the second
08/01/18
Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will report its second quarter 2018 financial results after market close on Wednesday, August 8 , 2018. Rigel senior management will follow the announcement with a live
06/26/18
Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
SOUTH SAN FRANCISCO, Calif. , June 26, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq: RIGL) today announced that it has initiated a Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects.

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)
Volume
Data as of
More »
Upcoming Events
More events are coming soon.

Stock Chart

Copyright Nasdaq. Minimum 15 minutes delayed.

What's New

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site